Gilead Sciences Wins First-Line Trodelvy Approval and Marks One Year of Lenacapavir HIV Prevention
Positive for
Gilead Sciences secured FDA approval for Trodelvy as a first-line treatment for triple-negative breast cancer, expanding the drug's commercial opportunity beyond later-line use. Separately, the company marked one year since the launch of its twice-yearly Lenacapavir HIV prevention injection, which has shown strong uptake, while positive Phase 3 data for Livdelzi in primary biliary cholangitis adds
Trodelvy Moves to First Line
Gilead Sciences received FDA approval to use Trodelvy (sacituzumab govitecan) as a first-line treatment for triple-negative breast cancer (TNBC). TNBC is an aggressive subtype that lacks the hormone receptors and HER2 amplification that make other breast cancer drugs effective, leaving patients with fewer targeted options. Trodelvy, an antibody-drug conjugate that delivers a chemotherapy payload directly to tumour cells, was previously approved in later lines of treatment. Moving to first-line use substantially expands the addressable patient population, first-line labels reach the broadest group of newly diagnosed patients before they have exhausted other options.
Cantor Fitzgerald reiterated its Overweight rating on GILD following the Trodelvy milestone, citing the drug's differentiated mechanism and the commercial opportunity in TNBC. Trodelvy approval in Europe for the same indication further extends its global revenue potential.
Lenacapavir: One Year of Twice-Yearly HIV Prevention
Gilead marked the one-year anniversary of the commercial launch of its twice-yearly injectable HIV prevention regimen based on lenacapavir. HIV prevention has historically relied on daily oral pre-exposure prophylaxis (PrEP) tablets, which require strict adherence. A twice-yearly injection dramatically reduces the adherence burden, and clinical results from the PURPOSE trials showed near-complete prevention of HIV acquisition. Uptake among high-risk populations in the US and expansion into lower-income countries, where Gilead has licensed generic production, represents both a commercial and public health opportunity at scale.
Phase 3 Win for Livdelzi in PBC
Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis (PBC), a chronic liver disease disproportionately affecting women. The positive data support continued commercialisation of Livdelzi, which received accelerated approval earlier and is now building towards full approval. PBC is a rare disease with limited treatment options, positioning Livdelzi as a meaningful addition to Gilead's liver disease portfolio, an area where the company has deep expertise from its history of developing hepatitis C and B treatments.
Sources
Frequently asked questions
What is Trodelvy and why does first-line approval matter?
Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate that delivers chemotherapy directly to tumour cells. First-line approval in triple-negative breast cancer means it can now be prescribed to newly diagnosed TNBC patients before they exhaust other treatments, expanding the pool of eligible patients significantly compared to its previous later-line approval.
What is lenacapavir and how does it prevent HIV?
Lenacapavir is an HIV capsid inhibitor developed by Gilead that can be given as a twice-yearly injection for HIV prevention (PrEP). Trials showed near-complete prevention of HIV acquisition, and unlike daily oral PrEP pills, the six-month dosing interval removes the need for daily adherence, making it potentially transformative for HIV prevention in high-risk populations.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
One story is a data point. The pattern is the edge.
Reading one story at a time, you miss how the news adds up. Track GILD free and TradeTidings rolls every future headline into one clear positive, neutral or negative read, and alerts you the moment it turns.